Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Squamous Cell Carcinoma of Head and Neck 44Lung Neoplasms 36Urinary Bladder Neoplasms 22Oropharyngeal Neoplasms 22Head and Neck Neoplasms 19Nasopharyngeal Carcinoma 18Carcinoma 16Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14Esophageal Squamous Cell Carcinoma 14Uterine Cervical Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Cholangiocarcinoma 13Ovarian Neoplasms 12Colorectal Neoplasms 12Pancreatic Neoplasms 11Carcinoma, Squamous Cell 11Laryngeal Neoplasms 10Stomach Neoplasms 9Mouth Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Mesothelioma, Malignant 6

Interventions

Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Carcinoma × Cisplatin × 90 days × Clear all
NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

Changhai Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡